Legato Capital Management LLC Trims Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Legato Capital Management LLC trimmed its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 23.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 114,820 shares of the biopharmaceutical company’s stock after selling 34,695 shares during the quarter. Legato Capital Management LLC owned 0.07% of Ocular Therapeutix worth $981,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in OCUL. Assenagon Asset Management S.A. bought a new stake in Ocular Therapeutix in the third quarter worth $24,584,000. Charles Schwab Investment Management Inc. boosted its holdings in Ocular Therapeutix by 146.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company’s stock worth $9,661,000 after acquiring an additional 660,080 shares in the last quarter. Braidwell LP boosted its holdings in Ocular Therapeutix by 36.3% in the third quarter. Braidwell LP now owns 2,239,770 shares of the biopharmaceutical company’s stock worth $19,486,000 after acquiring an additional 596,000 shares in the last quarter. Polar Asset Management Partners Inc. bought a new stake in Ocular Therapeutix in the third quarter worth $4,288,000. Finally, FMR LLC boosted its holdings in Ocular Therapeutix by 7,098.7% in the third quarter. FMR LLC now owns 434,369 shares of the biopharmaceutical company’s stock worth $3,779,000 after acquiring an additional 428,335 shares in the last quarter. 59.21% of the stock is owned by institutional investors.

Insider Activity

In other Ocular Therapeutix news, insider Donald Notman sold 11,119 shares of the stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total value of $86,839.39. Following the transaction, the insider now owns 193,444 shares of the company’s stock, valued at approximately $1,510,797.64. This represents a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jeffrey S. Heier sold 2,948 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $9.01, for a total value of $26,561.48. Following the completion of the transaction, the insider now directly owns 269,059 shares in the company, valued at approximately $2,424,221.59. This represents a 1.08 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,368 shares of company stock valued at $162,801 over the last ninety days. 3.50% of the stock is currently owned by corporate insiders.

Ocular Therapeutix Trading Up 0.4 %

Shares of NASDAQ:OCUL opened at $7.48 on Friday. The company has a market cap of $1.18 billion, a P/E ratio of -5.67 and a beta of 1.22. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. Ocular Therapeutix, Inc. has a 1 year low of $4.06 and a 1 year high of $11.77. The stock’s fifty day moving average price is $8.35 and its 200-day moving average price is $8.99.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $17.00.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.